-84%

est. 2Y upside i

HealthcareAI & MLSeed

Foundation Model for the Brain

Rank

#360

Sector

HealthTech, Artificial Intelligence

Est. Liquidity

~6Y

Data Quality

Data: Medium

Piramidal presents a moderate upside opportunity for a job seeker, driven by its innovative foundational AI model for EEG analysis in a large, underserved HealthTech market.

Last updated: February 25, 2026

Bull (30%)+400%

Piramidal successfully navigates regulatory hurdles and achieves widespread adoption of its foundational AI model, securing key partnerships with major hospital systems beyond its initial customers. This leads to rapid market penetration in the $2.5B TAM, pushing revenue to $50M+ by 2028 and justifying a $125M+ valuation, a 5x return from the current seed valuation.

Base (35%)+100%

Piramidal establishes itself as a niche leader in AI-powered EEG diagnostics, achieving steady growth and securing a Series A round. It captures a meaningful share of the SAM, reaching ~$10M-$15M in ARR by 2028, leading to an acquisition or Series B valuation of $50M, a 2x return from the current seed valuation.

Bear (35%)-80%

Piramidal faces significant challenges with regulatory approvals or struggles to scale its clinical partnerships. Dominant incumbents like Boston Scientific or large AI labs enter the specialized EEG analysis space, commoditizing the technology. This results in a down round or acquisition at a significantly reduced valuation of $5M, wiping out most common stock value.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Investors hold $6M in liquidation preferences, representing 24% of the estimated current $25M post-money valuation.

Dilution Risk

high

As a seed-stage company, Piramidal will require multiple additional funding rounds (Series A, B, C, etc.), which will lead to significant dilution for early common stock holders.

Secondary Liquidity

none

There are no active secondary markets or tender offers for a company at this early stage.

View all 6 open roles at Piramidal →

Last updated: February 17, 2026

Questions to Ask at the Interview

Strategic questions based on Piramidal's data — designed to show you've done your homework.

  • 1

    “Given the high regulatory barriers in healthcare AI, what is Piramidal's specific strategy and timeline for obtaining necessary FDA approvals for its foundational AI model?”

  • 2

    “How does Piramidal plan to differentiate its foundational AI model from potential offerings by large medical device companies like Boston Scientific or general AI giants like Google, especially as they expand into neurological diagnostics?”

  • 3

    “As a seed-stage company, what are the key milestones Piramidal aims to achieve in the next 12-18 months to de-risk the business and attract a strong Series A round, and how will these impact employee equity?”

Community

Valuation Sentiment

Our model estimates -84% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.